SCHEMBL498539

SCHEMBL498539

COc1ccc(C=O)cc1OC1Cc2ccccc2C1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.60
TSHR P16473 1/20 0.60
PDE4B Q07343 8/20 0.57
PDE4A P27815 5/20 0.57
PDE4C Q08493 5/20 0.57
PDE4D Q08499 5/20 0.57
TTR P02766 1/20 0.52
FDPS P14324 1/20 0.49
ALDH1A3 P47895 1/20 0.48
AOX1 Q06278 1/20 0.47
TRIM24 O15164 1/20 0.47
HPGD P15428 1/20 0.47
ALDH5A1 P51649 1/20 0.47
ABAT P80404 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
TRIM33 Q9UPN9 1/20 0.47
MAPT P10636 2/20 0.45
NPC1 O15118 1/20 0.45
HTT P42858 1/20 0.45
RAB9A P51151 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22713946 0.84 ALDH1A1 (0.68) ALDH1A1TSHRPDE4BPDE4APDE4C
SCHEMBL6883557 0.83 ALDH1A1 (0.66) ALDH1A1TSHRPDE4BPDE4APDE4C
SCHEMBL5359095 0.83 PDE4B (0.56) ALDH1A1TSHRPDE4BPDE4APDE4C
SCHEMBL5359098 0.83 PDE4B (0.56) ALDH1A1TSHRPDE4BPDE4APDE4C
SCHEMBL5355223 0.82 PDE4B (0.58) PDE4BPDE4APDE4CPDE4DTDP1
SCHEMBL5355215 0.82 PDE4B (0.58) PDE4BPDE4APDE4CPDE4DTDP1
SCHEMBL70835 0.82 ALDH1A1 (0.64) ALDH1A1TSHRPDE4BPDE4APDE4C
SCHEMBL70252 0.82 ALDH1A1 (0.64) ALDH1A1TSHRPDE4BTTRFDPS
SCHEMBL29808190 0.82 ALDH1A1 (0.64) ALDH1A1TSHRPDE4BPDE4APDE4C
SCHEMBL7560477 0.82 ALDH1A1 (0.64) ALDH1A1TSHRPDE4BPDE4APDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2157084-B1 5-PHENYL-3-PYRIDAZINONE DERIVATIVE KOWA CO (JP) 2013-05-22 EP disclosed
US-8106053-B2 5-phenyl-3-pyridazinone derivative KOWA COMPANY, LTD. 2012-01-31 US disclosed
US-20100197698-A1 5-PHENYL-3-PYRIDAZINONE DERIVATIVE KOWA COMPANY, LTD. (JP) 2010-08-05 US disclosed
EP-2157084-A1 5-PHENYL-3-PYRIDAZINONE DERIVATIVE Kowa Company, Ltd. (JP) 2010-02-24 EP disclosed
EP-1468991-B1 Imides as PDE III, PDE IV and TNF inhibitors CELGENE CORP (US) 2008-02-20 EP disclosed
US-7176229-B2 Cyclic AMP-specific phosphodiesterase inhibitors ICOS CORPORATION (US) 2007-02-13 US disclosed
US-7176229-B2 Cyclic AMP-specific phosphodiesterase inhibitors ICOS CORPORATION (US) 2007-02-13 US disclosed
US-7176229-B2 Cyclic AMP-specific phosphodiesterase inhibitors ICOS CORPORATION (US) 2007-02-13 US disclosed
US-20060264477-A1 Methods of using cyclic amides MULLER GEORGE W 2006-11-23 US disclosed
US-7081464-B2 Topical compositions of cyclic amides as immunotherapeutic agents CELGENE CORPORATION (US) 2006-07-25 US disclosed
WO-1998014432-A1 PDE IV INHIBITING 2-CYANOIMINOIMIDAZOLE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 1998-04-09 WO disclosed
US-5728844-A INHIBITORS OF TUMOR NECROSIS AND PHOSPHODIESTERASE CELGENE CORPORATION (US) 1998-03-17 US disclosed
WO-1997023457-A1 IMIDES AS PDE III, PDE IV AND TNF INHIBITORS CELGENE CORPORATION (US) 1997-07-03 WO disclosed
US-5459145-A Calcium independent camp phosphodiesterase inhibitor antidepressant PFIZER INC. (US) 1995-10-17 US disclosed
US-5294730-A A-Amino-4-alkoxy-3-polycycloalkyloxybenzyl cyanide derivatives PFIZER INC. (US) 1994-03-15 US disclosed
EP-0247725-B1 Calcium independent camp phosphodiestrerase inhibitor antidepressant PFIZER (US) 1994-03-02 EP disclosed
US-5196426-A CALCIUM INDEPENDENT C AMP PHOSPHODIESTERASE INHIBITOR ANTIDEPRESSANT PFIZER INC. (US) 1993-03-23 US disclosed
US-5128358-A Aryl substituted nitrogen heterocyclic antidepressants PFIZER INC. (US) 1992-07-07 US disclosed
EP-0247725-A2 Calcium independent camp phosphodiestrerase inhibitor antidepressant PFIZER INC. (US) 1987-12-02 EP disclosed
WO-1987006576-A1 CALCIUM INDEPENDENT CAMP PHOSPHODIESTERASE INHIBITOR ANTIDEPRESSANT PFIZER INC. (US) 1987-11-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197698-A1 5-PHENYL-3-PYRIDAZINONE DERIVATIVE SERPINE1, MMP1, PLAT ALDH1A1 818/4885TSHR 3650/4885PDE4B 1932/4885
US-20060264477-A1 Methods of using cyclic amides RNASE1, RNGTT, CGAS ALDH1A1 3605/4885TSHR 2122/4885PDE4B 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.